Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Evaluation of the Safety of PS 341 in the Treatment of Recurrent Gliomas

NCT00006773 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00006773
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00006773 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Evaluation of the Safety of PS 341 in the Treatment of Recurrent Gliomas
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Terminated
Start date
May 31, 2001
Completion date
Not reported
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult anaplastic astrocytoma, adult anaplastic oligodendroglioma, adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, recurrent adult brain tumor